A carregar...
Cost–utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels
BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause. Characterizing the cost–utility (cu) of this therapy could help to determine its role in clinical...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4530821/ https://ncbi.nlm.nih.gov/pubmed/26300674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2383 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|